Table 3.
Logistic regression analysis (adjusting PSA and clinical T stage)
| Univariable analysis | Multivariable analysis | |||
|---|---|---|---|---|
| OR (95% CI) | p-value | OR (95%CI) | p-value | |
| RP GS upgrading | ||||
|
GG 4 Reference GS 3 + 5 |
0.0012 | 0.004 | ||
| GS 4 + 4 | 1.01 (0.68–1.50) | 0.97 | 0.92 (0.68–1.54) | 0.92 |
| GS 5 + 3 | 3.43 (1.68–6.99) | 0.0007 | 3.24 (1.54–6.83) | 0.002 |
| Reference GS 4 + 4 | ||||
| GS 5 + 3 | 3.40 (1.83–6.32) | 0.0001 | 3.17 (1.65–6.08) | 0.0005 |
| Extraprostatic extension | ||||
|
GG 4 Reference GS 3 + 5 |
0.26 | 0.33 | ||
| GS 4 + 4 | 0.91 (0.67–1.24) | 0.55 | 0.83 (0.60–1.15) | 0.27 |
| GS 5 + 3 | 1.51 (0.75–3.03) | 0.25 | 1.21 (0.57–2.58) | 0.63 |
| Reference GS 4 + 4 | ||||
| GS 5 + 3 | 1.65 (0.87–3.15) | 0.13 | 1.45 (0.72–2.93) | 0.30 |
| Lymph node metastasis | ||||
|
GG 4 Reference GS 3 + 5 |
0.04 | 0.18 | ||
| GS 4 + 4 | 1.05 (0.71–1.56) | 0.81 | 1.03 (0.67–1.58) | 0.89 |
| GS 5 + 3 | 2.52 (1.21–5.23) | 0.01 | 2.10 (0.92–4.76) | 0.08 |
| Reference GS 4 + 4 | ||||
| GS 5 + 3 | 2.39 (1.26–4.54) | 0.008 | 2.03 (0.98–4.20) | 0.06 |
| Non-organ confined disease | ||||
|
GG 4 Reference GS 3 + 5 |
0.21 | 0.28 | ||
| GS 4 + 4 | 0.92 (0.68–1.25) | 0.61 | 0.83 (0.60–1.16) | 0.28 |
| GS 5 + 3 | 1.60 (0.79–3.28) | 0.19 | 1.30 (0.60–2.81) | 0.50 |
| Reference GS 4 + 4 | ||||
| GS 5 + 3 | 1.74 (0.90–3.37) | 0.10 | 1.56 (0.76–3.19) | 0.22 |
| Positive surgical margin | ||||
|
GG 4 Reference GS 3 + 5 |
0.53 | 0.82 | ||
| GS 4 + 4 | 0.94 (0.66–1.32) | 0.71 | 0.90 (0.63–1.31) | 0.59 |
| GS 5 + 3 | 1.35 (0.66–2.76) | 0.41 | 1.03 (0.46–2.30) | 0.94 |
| Reference GS 4 + 4 | ||||
| GS 5 + 3 | 1.44 (0.75–2.75) | 0.27 | 1.14 (0.55–2.37) | 0.72 |
CI confidence interval, GG grade group, GS Gleason score, OR odds ratio, PSA prostate-specific antigen, RP radical prostatectomy
Bold p values are considered statistically significant (p value < 0.05)